Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737052 | 0.87 | KCNH2 (0.39) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL14439807 | 0.85 | KCNH2 (0.38) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL14439809 | 0.84 | KCNH2 (0.35) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL6957548 | 0.84 | KCNH2 (0.35) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL8343685 | 0.84 | KCNH2 (0.37) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL5852651 | 0.84 | KCNH2 (0.35) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL6974439 | 0.84 | KCNH2 (0.33) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL6967722 | 0.83 | TDP1 (0.34) | KCNH2TDP1HSP90B1TRAP1HTT | |
| SCHEMBL7077305 | 0.82 | KCNH2 (0.34) | KCNH2TDP1HSP90B1TRAP1 | |
| SCHEMBL6973648 | 0.82 | KCNH2 (0.34) | KCNH2TDP1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | claimed |
| EP-1591444-B1 | CCR5 antagonists useful for treating aids | SCHERING CORP (US) | 2010-04-28 | — | — | EP | claimed |
| EP-1569931-B1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1569647-B1 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1569933-B1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1172097-B1 | PROCESS FOR PRODUCING MEDICINAL COMPOSITION OF A BASIC HYDROPHOBIC MEDICINAL COMPOUND | SHIONOGI & CO (JP) | 2004-09-08 | — | — | EP | claimed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2225239-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-1730120-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090317-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |